These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30266781)

  • 1. Canadian status of "drugs to avoid" in 2017: a descriptive analysis.
    Lexchin J
    CMAJ Open; 2018; 6(3):E430-E435. PubMed ID: 30266781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study.
    Lexchin J
    PLoS One; 2024; 19(8):e0308118. PubMed ID: 39088553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Canada's use of its priority review process for new drugs: a cohort study.
    Lexchin J
    BMJ Open; 2015 May; 5(5):e006816. PubMed ID: 25967989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.
    Lexchin J
    Int J Risk Saf Med; 2015; 27(3):135-42. PubMed ID: 26410247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study.
    Lexchin J
    Healthc Policy; 2016 Nov; 12(2):65-75. PubMed ID: 28032825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers.
    Foroutan N; Tarride JE; Xie F; Mills F; Levine M
    Pharmacoecon Open; 2019 Dec; 3(4):437-451. PubMed ID: 31041614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.
    Balijepalli C; Gullapalli L; Druyts E; Yan K; Desai K; Barakat S; Locklin J
    Clinicoecon Outcomes Res; 2020; 12():445-457. PubMed ID: 32922050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
    Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
    Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines.
    Foroutan N; Tarride JE; Xie F; Jameel B; Mills F; Levine M
    J Popul Ther Clin Pharmacol; 2020 Jan; 27(1):e1-e24. PubMed ID: 31922700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marketing before patenting: implications for price controls in Canada.
    Lexchin J
    Open Med; 2010; 4(3):e139-42. PubMed ID: 21687333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic competition in Canada.
    Steele JW
    Pharmacoeconomics; 1994 Nov; 6(5):480-2. PubMed ID: 10155276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Drugs to avoid" to improve quality use of medicines: how is Australia faring?
    Vitry A; Mintzes B
    J Pharm Policy Pract; 2021 Jul; 14(1):60. PubMed ID: 34256874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
    Meyers DE; Jenei K; Chisamore TM; Gyawali B
    JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
    Lexchin J
    BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
    Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
    Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.